ストックスクリーナーアプリを入手
16.51
4.68%
-0.81
Janux Therapeutics Inc (JANX) 最新ニュース
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? - Zacks Investment Research
Janux Therapeutics (NasdaqGM:JANX) Stock Forecast & Analyst Predictions - Simply Wall Street
The first patient gets Janux's new immune treatment in a prostate cancer trial. - Stock Titan
Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily
Janux’s JANX014 Prostate Cancer Trial Advances, Keeping Early-Stage Upside in Play - TipRanks
Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - qz.com
Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - Moomoo
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com Canada
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com India
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com UK
Wolfe Research upgrades Janux stock rating on autoimmune data - investing.com
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know - TradingView
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - Sahm
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - simplywall.st
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - simplywall.st
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the DayEstimate Revision Count - vinanet.vn
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sprott (SII) Trading Review: Retreats 3.40% to $117.79 for the Current Session; Price Context: Traders Can Monitor the $111.90-$123.68 Range under the Current SnapshotBollinger Walk - careplusvn.com
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund - stocktitan.net
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management - stocktitan.net
William Blair Maintains Janux Therapeutics(JANX.US) With Buy Rating - moomoo.com
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Janux Therapeutics (JANX) Gains 0.91% as Shares Firmly Hold Above $15.84 SupportHigh Conviction Picks - Vinanet
Equities Analysts Set Expectations for JANX Q3 Earnings - MarketBeat
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings - MarketBeat
Why (JANX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile - Yahoo Finance
Janus Living Prices Share Offering - marketscreener.com
Janus Living Prices Share Offering - Moomoo
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - Moomoo
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results - simplywall.st
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - marketscreener.com
Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - theglobeandmail.com
Janux Therapeutics Inc (JANX) Stock News Today - TradingKey
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside - TradingView
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
JANX Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusRevenue Guidance Update - vinanet.vn
Janux Therapeutics earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Janux Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Janux Therapeutics 2Q 2026: Revenue $10.3M, EPS $(0.35) — 10-Q Summary - TradingView
JANX: Clinical pipeline advanced and net loss narrowed, supported by nearly $1B in liquidity - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M - marketscreener.com
3.96%
1.31%
大文字化:
|
ボリューム (24 時間):